2. UroToday Home
  3. Trials in Progress

Trials in Progress

ARAMON: A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer

Trials in Progress
Videos

A 2-stage, Lead-in and Randomized, Phase 2, Open-label Study of Darolutamide Versus Enzalutamide as Monotherapy on Testosterone Levels Change in Men With Hormone-Naïve Prostate Cancer

  • Condition: Biochemically Recurrent Prostate Cancer
  • Study ID: NCT05526248
View Trial
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Xin Gao, MD
The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Xin Gao discussing lead-in phase results of the ARAMON trial assessing darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence.
Presented by Andrew Laccetti, MD, MS
(UroToday.com) The 2024 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to a prostate cancer trials in progress poster session. Dr. Andrew Laccetti presented ARAMON, a phase 2, randomized, open-label study comparing darolutamide and enzalutamide monotherapy’s effects on serum testosterone levels in patients with castration-sensitive prostate cancer in the setting of biochemical recurrence.
Presented by Xin Gao, MD
(UroToday.com) The 2023 ASCO annual meeting included a prostate cancer session, featuring a trials in progress presentation by Dr. Xin Gao discussing ARAMON, a phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer.